PlainPharmaWatch

CMS Open Payments · Program Year 2024

Coloplast Corp

Coloplast Corp reported $5,997,453.26 across General Payments, Research, and Ownership to 19,137 physicians and teaching hospitals across 19,420 transactions.

See the rankings → How this is sourced
$6.0M Top quartile payer
All-tracks total
19,420 Top 10% volume
Transactions
19,137 Top 10% reach
Recipients
−$228.9K
General Payments vs PY2023

Coloplast Corp reported $5,997,453.26 across all CMS Open Payments tracks (General + Research + Ownership) to 19,137 physicians and teaching hospitals in Program Year 2024 - ranking #243 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $3,395,796.08, averaging $313.40 per recipient.

How Coloplast Corp's $6.0M all-tracks total breaks down

Coloplast Corp's payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

B

86/100

Total payments

C

65/100

Transaction volume

A

100/100

Physician reach

A

100/100

Payment type diversity

C

77/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer coloplast-corp Coloplast Corp

$6.0M · #243/1,925 · 0.0% industry · PY2024

  • TOT $6.0M
  • RANK #243
  • SHARE 0.0%
  • TXN 19,420
  • RCP 19,137
  • CAT 6
  • GEN $3.4M
  • ΔGEN −$228.9K
  • TOP1 12.8%
  • PY 2024

Volume peers

Nearest volume peer: Envista Holdings Corporation ($6.0M)

Cook Incorporated$6.0MTeleflex LLC$6.0MColoplast Corp (this)$6.0MEnvista Holdings Corporation$6.0MVentana Medical Systems, Inc.$5.9M
All-tracks payment totals near Coloplast Corp (CMS Open Payments PY2024)

Coloplast Corp sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Coloplast Corp's CMS-reported General Payments decreased by $228.9K (−6.3%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: COLOPLAST CORPPY2023: COLOPLAST CORPPY2024: COLOPLAST CORP. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$3.6MPY2024$3.4M
PY2023
$3,624,745.29
PY2024
$3,395,796.08

What the Data Shows for Coloplast Corp

CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Coloplast Corp, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.

Of the 6 general-payment categories charted below, "Consulting Fee" is the largest at $1.8M across 385 transactions, 52.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 6 types of general payments, Coloplast Corp's largest category was "Consulting Fee" at $1.8M - 52.8% of General Payments.

Coloplast Corp reports 6 general-payment categories - the top three are Consulting Fee (52.8%), Food and Beverage (22.6%), and Travel and Lodging (13.4%). The remaining 3 categories make up 11.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Coloplast Corp divides its payments

How the reported total splits across payment categories

1. Consulting Fee$1.8M2. Food and Beverage$767.1K3. Travel and Lodging$453.9K4. Grant$319.9K5. Debt Forgiveness$33.9K6. Royalty or License$26.9K
Payment Type Amount Transactions
Consulting Fee $1.8M 385
Food and Beverage $767.1K 17,332
Travel and Lodging $453.9K 1,397
Grant $319.9K 6
Debt Forgiveness $33.9K 13
Royalty or License $26.9K 4

Recipient Concentration in General Payments

The five largest recipient relationships account for $823,677.30 (24.3%) of $3,395,796.08 in this company's General Payments records across 6,456 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Coloplast Corp

The five named recipients with the highest reported General Payments from this company

Paul E. Perito$435.5KUniversity Of Washington Med…$141.8KMontefiore Medical Center$100.0KUci Medical Center$74.8KVincent Lucente$71.6K
  1. 1

    Paul E. Perito

    $435,478.69 across 124 reported transactions

  2. 2

    University Of Washington Med Ctr

    $141,841.00 across 1 reported transactions

  3. 3

    Montefiore Medical Center

    $100,000.00 across 1 reported transactions

  4. 4

    Uci Medical Center

    $74,800.00 across 1 reported transactions

  5. 5

    Vincent Lucente

    $71,557.61 across 66 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Coloplast Corp ranks #243 of 1,925 by total payments (top 13% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,514 of 1,838 by HHI (bottom 18% least concentrated), a wider distribution than most similarly sized payers.

031.062.092.9123.9238.5241.3244246.8249.5Total payments ($M)Concentration (HHI, 0-10,000)
Coloplast Corp (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Coloplast Corp's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Coloplast Corp.

Medtronic, Inc.

HHI 247

Prism Medical

HHI 247

Recordati_rare_diseases_inc.

HHI 247

Verrica Pharmaceuticals Inc.

HHI 248

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Coloplast Corp.

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Coloplast Corp ranks #243 of 1,925 by all-tracks total payments, led by "Consulting Fee".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Coloplast Corp's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.